vimarsana.com
Home
Live Updates
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections : comparemela.com
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events or serious AEs . Positive trends in clearance rate for both high-risk HPV...
Related Keywords
United Kingdom ,
Ukraine ,
Israel ,
United States ,
Gaza ,
Israel General ,
American ,
Barinthus Bio ,
Barinthus Biotherapeutics ,
Christopherm Calabrese ,
Kevin Gardner ,
Jonothan Blackbourn ,
Audra Friis ,
Nadege Pelletier ,
Exchange Commission ,
Womens Health Lond ,
Sam Brown Inc ,
Nasdaq ,
American Cancer Society ,
Bill Enright ,
Chief Executive Officer ,
Chief Scientific Officer ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Cervical Cancer ,
Cancer Society ,
Key Statistics ,
comparemela.com © 2020. All Rights Reserved.